Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00780494 · ClinicalTrials.gov registry record · Phase 2
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
A Phase 2 study of Stomach Cancer and Gastrointestinal Stromal Tumor (GIST), sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00780494 is a Phase 2 study of Stomach Cancer and Gastrointestinal Stromal Tumor (GIST) that has completed, run by Stanford University. The registered enrollment target is 35 participants, below the 633-participant average among 15 other Stomach Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00780494, a Phase 2 study of Stomach Cancer and Gastrointestinal Stromal Tumor (GIST), has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
To investigate bevacizumab in combination with carboplatin and capecitabine for patients with unresectable or metastatic GEJ or gastric cancers. We hope that by adding bevacizumab to standard chemotherapy for this patient population we will improve Progression Free Survival by 90% over historical controls.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG bevacizumab
- DRUG capecitabine
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2009-02 |
| Est. Completion | 2017-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00780494
The ClinicalTrials.gov registry entry for NCT00780494 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 633-participant average among 15 other Stomach Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Stomach Cancer appearing as the primary indexed condition, and to 3 interventions - of which carboplatin is the first listed.
NCT00780494 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00780494 about?
NCT00780494 is a clinical study titled "Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma". To investigate bevacizumab in combination with carboplatin and capecitabine for patients with unresectable or metastatic GEJ or gastric cancers. We hope that by adding bevacizumab to standard chemotherapy for this patient population we will improve Progression Free Survival by 90% over historical co...
What is the current status of trial NCT00780494?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2009-02. Estimated completion is 2017-12-31.
What conditions does trial NCT00780494 study?
This clinical trial studies the following conditions: Stomach Cancer, Gastrointestinal Stromal Tumor (GIST), Gastric (Stomach) Cancer, Neoplasm of Cardioesophageal Junction.
What interventions are being tested in trial NCT00780494?
The interventions under investigation include: carboplatin (DRUG), bevacizumab (DRUG), capecitabine (DRUG).
Who is sponsoring clinical trial NCT00780494?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00780494 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stomach Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
RECRUITING · Phase 2
-
Avutometinib and Defactinib in Diffuse Gastric Cancer
RECRUITING · Phase 2
-
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer
COMPLETED · Phase 2
-
Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
COMPLETED · Phase 2
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.